Mark Trisna, DO
Hospitalist · Houston, TXNPI 1669799581
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 30 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 12 manufacturers reported payments, led by Johnson & Johnson at 24.0% of the total. Reporting peaked in 2023 at $235 and has fallen 54.4% since, to $107 in 2024.
Across 30 payments — averaging $17.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$128
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$92
- Boehringer Ingelheim$58
- La Jolla Pharmaceutical Company$53
- AbbVie$42
- Boston Scientific$39
- plus $121 from 6 others
What the payments were for
- Food & beverage$532100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 8 | $128 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 6 | $92 |
| Boehringer Ingelheim | 2 | $58 |
| La Jolla Pharmaceutical Company | 3 | $53 |
| AbbVie | 2 | $42 |
| Boston Scientific | 2 | $39 |
| Novartis | 2 | $38 |
| E.r. Squibb & Sons, L.L.C. | 1 | $20 |
| Novo Nordisk | 1 | $20 |
| Mylan Specialty L.p. | 1 | $18 |
| AstraZeneca | 1 | $14 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $12 |
How this compares
$532 in reported general payments places this provider in the 80th percentile of 1,284 hospitalist providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Pantoprazole Sodium | 38 | $328 |
| Metoprolol Succinate | 35 | $235 |
| Cefdinir | 17 | $210 |
| Levetiracetam | 12 | $112 |
| Atorvastatin Calcium | 20 | $80 |
| Furosemide | 24 | $45 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 13 | $45 |
| Lisinopril | 13 | $37 |
Paid to pharmacies, not to this prescriber.
Other hospitalist in Houston
- Ryan NealHouston$154K
- Ahmad BaroutHouston$44K
- Laxman KalvakuntlaHouston$30K
- Joshua HahnHouston$23K
- Grace OdiHouston$14K
- Spencer SuHouston$9K
- Martin Chacon PortilloHouston$9K
- Abeer SiddiqiHouston$9K
- Brent GudenkaufHouston$8K
- Dilpreet SinghHouston$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.